Movement Disorder Society (MDS)
27^th International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, Denmark (Aug. 27-31, 2023)

• Jankovic J, Oh C, Liu Y, Comella C. A phase 2, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ABP-450 (prabotulinumtoxinA) in adults with isolated cervical dystonia. Mov Disord. 2023;38(suppl 1):S349. 

American Academy of Neurology (AAN)
75^th Annual Meeting in Boston, Mass. (April 22-28, 2023)

• Dashtipour K, Jankovic J, Charles D, Mehta S, Schwartz M, Sadeghi M. Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis and retrocollis. Presented at the American Academy of Neurology (AAN), 75^th Annual Meeting in Boston, Mass. (April 22-28, 2023).  
• Hull M, Parnes M, Jankovic J. Spinocerebellar ataxia 21 and phenotypic variability within a single family. Presented at the American Academy of Neurology (AAN), 75^th Annual Meeting in Boston, Mass. (April 22-28, 2023).  

Movement Disorder Society (MDS)
26^th International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain (Sept. 15-18, 2022)

• Dashtipour K, Jankovic J, Charles D, Mehta S, Schwartz M, Sadeghi M. Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis subtype of cervical dystonia. Mov Disord. 2022;37 Suppl 2:S259. 
• Dashtipour K, Jankovic J, Charles D, Mehta S, Schwartz M, Sadeghi M. Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with retrocollis subtype of cervical dystonia. Mov Disord. 2022;37 Suppl 2:S259. 
• Hull M, Parnes M, Jankovic J. Spinocerebellar ataxia 21 and phenotypic variability within a family. Mov Disord. 2022;37 Suppl 2:S213. 
• Vu J, Cisneros E, Zhao J, Jankovic J, Factor S, Goetz C, et al. How does head tremor in cervical dystonia change with head position? Mov Disord. 2022;37 Suppl 2:S207. 

International Neurotoxin Association (INA)
Toxins 2022 6^th International Conference in New Orleans, La. (July 27-30, 2022)

• Dashtipour K, Jankovic J, Charles D, Mehta S, Schwartz M, Sadeghi M. Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis and retrocollis. Toxicon. 2022;214(Suppl 1):S59. 

American Academy of Neurology (AAN)
74^th Annual Meeting in Seattle, Wash. (April 2-7, 2022)

• Jankovic J, Carruthers J, Naumann M, Boodhoo T, Gupta S, Attar M, et al. Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: A meta-analysis. Neurology. 2022;98(18 suppl):3329. [Previously Presented] 
• Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al. A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia. Neurology. 2022;98(18 suppl):2418. 

Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021)

• Billnitzer A, Jankovic J. Pilot study to evaluate pimavanserin for the treatment of motor and behavioral symptoms of Tourette syndrome. Presented at the Movement Disorder Society (MDS), Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021).   [View poster]
• Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al. A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia. Presented at the Movement Disorder Society (MDS), Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021).  
• Makhoul K, Jankovic J. Tourette syndrome and driving. Presented at the Movement Disorder Society (MDS), Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021).   [View poster]
• Shah C, Robak L, Hill EJ, Jankovic J. Whole-exome sequencing in a movement disorders clinic. Presented at the Movement Disorder Society (MDS), Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021).   [View poster]
• Vollstedt E-J, Aasly JO, Ahmad-Annuar A, Al Mubarak B, Alcalay RN, Alvarez V, et al. The MJFF global genetic Parkinson's disease research resource. Presented at the Movement Disorder Society (MDS), Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021).  

American Academy of Neurology (AAN)
Virtual 2021 Annual Meeting (April 17-22, 2021)

• Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al. A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia. Neurology. 2021;96(15 Suppl):1478. 

International Neurotoxin Association (INA)
Virtual Conference (Jan. 16-17, 2021)

• Jankovic J, Carruthers J, Naumann M, Boodhoo T, Gupta S, Attar M, et al. Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: A meta-analysis. Toxicon. 2021;190(Suppl 1):S35. 
• Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al. A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia. Toxicon. 2021;190(Suppl 1):S34-5. 
• Mitsikostas DD, Dekundy A, Althaus M, Scheschonka A, Pagan F, Jankovic J. Duration of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naive subjects: Results from a phase III study. Toxicon. 2021;190(Suppl 1):S50. 

Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 12-16, 2020)

• Bayram E, Jankovic J, Reich S, Marras C, Bordelon Y, Shprecher D, et al. Cognitive differences between men and women with progressive supranuclear palsy. Mov Disord. 2020;35 Suppl 1:S502-3. 
• Pagan F, Dekundy A, Althaus M, Scheschonka A, Jankovic J, Mitsikostas D. Duration of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: Results from a Phase III study. Mov Disord. 2020;35 Suppl 1:S45-6. 

American Academy of Neurology (AAN)
72^nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)

• Hill E, Deger J, Robak L, Rao S, Saade H, Ripperger B, et al. Addressing challenges of clinical comprehensive genetic testing in Parkinson's disease. Neurology. 2020;94(15 Suppl):5267. 

American Academy of Neurology (AAN)
71^st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)

• Alfradique-Dunham I, Blauwendraat C, Al-Ouran R, von Coelln R, Tan M, Hill EJ, et al. Genome-wide association study meta-analysis for Parkinson disease motor subtypes. Neurology. 2019;92(15 Suppl):S53.005. [Platform Presentation] 
• Brashear A, Truong DD, Comella CL, Jankovic J, Patel AT, Prawdzik G, et al. Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study. Neurology. 2019;92(15 Suppl):P4.8-012. 
• Claassen DO, Mink JW, Parnes M, Gordon MF, Barkay H, Wieman M, et al. RECLAIM-DCP: A randomized, double-blind, placebo-controlled study of deutetrabenazine for the treatment of dyskinesia in cerebral palsy in children and adolescents. Neurology. 2019;92(15 Suppl):P4.8-036. 
• Hill EJ, Alfradique-Dunham I, Mangleburg CG, Ripperger B, Stillwell A, Rao S, et al. Capturing Parkinson's disease heterogeneity with quantitative mobility measures. Neurology. 2019;92(15 Suppl):S10.006. [Platform Presentation] 
• Parnes M, Bashir HH, Jankovic J. Bradykinesia, mitochondrial myopathy and progressive ophthalmoplegia associated with a novel DNM1L mutation. Neurology. 2019;92(15 Suppl):P3.8-014. 

Huntington Study Group (HSG)
Annual Meeting in Houston, Texas (Nov. 8-10, 2018)

• Niemann N, Jankovic J. Real world experience with novel VMAT2 inhibitors. Presented at the Huntington Study Group (HSG), Annual Meeting in Houston, Texas (Nov. 8-10, 2018).   [View poster]
• Savitt D, Jankovic J. Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. Presented at the Huntington Study Group (HSG), Annual Meeting in Houston, Texas (Nov. 8-10, 2018).   [View poster]

Movement Disorder Society (MDS)
22^nd International Congress of Parkinson's Disease and Movement Disorders in Hong Kong, China (Oct. 5-9, 2018)

• Comella C, Brashear A, Jankovic J, Truong D, Patel A, Evatt M, et al. Improvement in patient perceived quality of life with daxibotulinumtoxinA for injection in adults with cervical dystonia. Mov Disord. 2018;33 Suppl 2:S18-9. 
• Junker J, Brandt V, Berman B, Vidailhet M, Roze E, Weissbach A, et al. Predictors of alcohol responsiveness in dystonia. Mov Disord. 2018;33 Suppl 2:S352-3. 
• Margraf N, Wolke R, Granert O, Berardelli A, Berg D, Bloem B, et al. Consensus for the measurement of the camptocormia angle. Mov Disord. 2018;33 Suppl 2:S464-5. 
• Robak L, Du R, Yuan B, Gu S, Akdemir Z, Jankovic J, et al. Integrated whole exome sequencing and chromosomal microarray in familial Parkinson's disease. Mov Disord. 2018;33 Suppl 2:S606. 
• Shoeibi A, Litvan I, Juncos J, Bordelon Y, Riley D, Reich S, et al. Accuracy of the International Parkinson Disease and Movement Disorder Society progressive supranuclear palsy diagnostic criteria (IPD-MDS-PSP). Mov Disord. 2018;33 Suppl 2:S433. 
• Sun Y, Hui Q, Perlmutter J, Ruehl S, Klein C, Jankovic J, et al. Genome-wide association study identifies common genetic variants associated with cervical dystonia. Mov Disord. 2018;33 Suppl 2:S315-6. 
• vander Linden C, Colle H, Colle D, Jankovic J. Erotophonophilia and severe impulse control disorder in a patient with Parkinson's disease. Mov Disord. 2018;33 Suppl 2:S823. 

American Academy of Neurology (AAN)
70^th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)

• Alfradique-Dunham I, Robak L, Kaw A, Fagbongbe OI, Akdemir ZC, Young E, et al. Whole exome sequencing in essential tremor. Neurology. 2018;90(15 Suppl):P6.061.  [View poster]
• Jankovic J, Truong D, Patel A, Brashear A, Evatt M, Rubio R, et al. Outcomes of week-24 completers and subjects who had follow-up beyond week 24 after a single treatment of daxibotulinumtoxinA for injection (RT002): Results of a phase 2, open-label (level II), dose escalating study in isolated cervical dystonia. Neurology. 2018;90(15 Suppl):P5.037. 
• Mahajan A, Jankovic J, Marsh L, Patel A, Jinnah HA, Comella C, et al. Cervical dystonia and substance abuse. Neurology. 2018;90(15 Suppl):P5.061. 
• Mitchell K, Peichel D, Wharen R, Okun M, Guthrie B, Uitti R, et al. Unilateral versus bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Neurology. 2018;90(15 Suppl):S18.003. [Platform Presentation] 
• Niemann N, Jankovic J. Phenomenology of leg stereotypy syndrome. Neurology. 2018;90(15 Suppl):P6.045.  [View poster]
• Parnes M, Bashir H, Jankovic J. Is benign hereditary chorea really benign? Brain-lung-thyroid syndrome caused by NKX2-1 mutations. Neurology. 2018;90(15 Suppl):P6.085.  [View poster]
• Savitt D, Jankovic J. Levodopa induced dyskinesias in neurodegeneration with brain iron accumulation due to a heterozygous mutation in C19orf12. Neurology. 2018;90(15 Suppl):P6.088.  [View poster]

Movement Disorder Society (MDS)
21^st International Congress of Parkinson's Disease and Movement Disorders in Vancouver, BC, Canada (June 4-8, 2017)

• Alfradique-Dunham I, Robak LA, Kaw A, Fagbongbe OI, Ternes K, Young E, et al. Whole exome sequencing in essential tremor. Mov Disord. 2017;32 Suppl 2:S294.  [View poster]
• Comella C, Jankovic J, Truong D, Brashear A, Patel A, Evatt M, et al. A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia. Mov Disord. 2017;32 Suppl 2:S773. [Previously Presented] 
• Dashtipour K, Mari Z, Jankovic J, Adler C, Schwartz M, Brin M. Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD probe study. Mov Disord. 2017;32 Suppl 2:S804-6. 
• Gatto E, Jinnah H, Espay A, Jankovic J, Bhatia K, Rodriguez M, et al. Treatable rare movement disorders. Mov Disord. 2017;32 Suppl 2:S412. 
• Gilbert D, Murphy T, Jankovic J, Budman C, Black K, Kurlan R, et al. A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome. Mov Disord. 2017;32 Suppl 2:S777-8. 
• Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, et al. Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease. Mov Disord. 2017;32 Suppl 2:S964. 
• Jankovic J, Lotia M, York MK, Strutt AM. Leg stereotypy disorder: Phenomenology and prevalence. Mov Disord. 2017;32 Suppl 2:S737.  [View poster]
• Scott B, Strutt A, Lundberg-Love P, Schmitt A, Jankovic J, Bowers D. Emotion regulation and neuropsychological status in psychogenic subtypes. Mov Disord. 2017;32 Suppl 2:S562. 
• Vijayakumar D, Lewis RA, Fuller GN, Dhar SU, Machol K, Robak L, et al. Hemidystonia associated with Alexander disease. Mov Disord. 2017;32 Suppl 2:S289.  [View poster]

American Academy of Neurology (AAN)
69^th Annual Meeting in Boston, Mass. (April 22-28, 2017)

• Comella C, Brashear A, Jankovic J, Patel A, Truong D, Evatt M, et al. A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia. Neurology. 2017;88(16 Suppl):P3.021. 
• Mari Z, Dashtipour K, Jankovic J, Adler CH, Schwartz M, Brin MF. Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD Probe study. Neurology. 2017;88(16 Suppl):P3.016. 
• Testa C, Edmondson M, Agarwal P, Blindauer K, Gray C, Jankovic J, et al. Assessment of capacity to consent in a Huntington disease clinical trial: Implications for future clinical trial design in neurodegenerative disease populations. Neurology. 2017;88(16 Suppl):P2.004.  [View poster]

International Neurotoxin Association (INA)
Toxins 2017 3^rd International Conference in Madrid, Spain (Jan. 18-21, 2017)

• Comella CL, Brashear A, Jankovic J, Patel AT, Truong DD, Chung CY, et al. A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxina for injection (RT002) in isolated cervical dystonia. Toxicon. 2017;123(Suppl):S18. 
• Dashtipour K, Mari Z, Jankovic J, Adler CH, Schwartz M, Brin MF Dashtipour K, et al. Clinical relevance of treatment with onabotulinumtoxina in patients with cervical dystonia: Results from the CD Probe study. Toxicon. 2017;123(Suppl):S20. 
• Jankovic J. Potential new uses of botulinum toxin injections in movement disorders. Toxicon. 2017;123(Suppl):S43. 
• Jankovic J, Schwartz M, Manack Adams A. Predictors of onabotulinumtoxinA response in patients with cervical dystonia. Toxicon. 2017;123(Suppl):S43-4. 

Movement Disorder Society (MDS)
20^th International Congress of Parkinson's Disease and Movement Disorders in Berlin, Germany (June 19-23, 2016)

• Bluett BR, Litvan I, Cheng S, Juncos J, Bordelon Y, Riley DE, et al. Understanding, predicting, and preventing falls in progressive supranuclear palsy. Mov Disord. 2016;31 Suppl 2:S82. 
• Gatto EM, Albanese A, Bathia K, Cardoso F, Cesarini M, Chade A, et al. Objectives of the MDS rare movement disorders study group. Mov Disord. 2016;31 Suppl 2:S134-5. 
• Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy TK, Shprecher D, et al. A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome. Mov Disord. 2016;31 Suppl 2:S307. 
• Jankovic J, Marc S, Aubrey A. Predictors of onabotulinumtoxinA treatment response in patients with cervical dystonia. Mov Disord. 2016;31 Suppl 2:S537-8. 
• Jankovic J, Vijayakumar D, Wijemanne S. Apraclonidine in blepharospasm. Mov Disord. 2016;31 Suppl 2:S532. 
• Wijemanne S, Vijayakumar D, Jankovic J. Apraclonidine in the treatment of ptosis. Mov Disord. 2016;31 Suppl 2:S693. 

American Academy of Neurology (AAN)
68^th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)

• Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, et al. A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome. Neurology. 2016;86(Meeting Abstracts 1):P1.046. 

Movement Disorder Society (MDS)
19^th International Congress of Parkinson's Disease and Movement Disorders in San Diego, Calif. (June 14-18, 2015)

• Fernandez HH, Jankovic J, Pagan F, Greeley D, Sethi K, Verma A. XCiDaBLE: Observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the USA. Mov Disord. 2015;30 Suppl 1:S508. 
• Fuentes A, Standaert D, Marras C, Riley D, Hall D, Kluger B, et al. Progressive supranuclear palsy and statin use. Mov Disord. 2015;30 Suppl 1:S314. 
• Jimenez-Shahed J, Keller J, Hunter C, Jankovic J. DBS experience at a tertiary care referral center. Mov Disord. 2015;30 Suppl 1:S223.  [View poster]
• Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al. American multiple system atrophy natural history study. Mov Disord. 2015;30 Suppl 1:S320. 
• Molho ES, Stacy M, Gillard P, Charles D, Adler CH, Jankovic J, et al. Cervical dystonia and work productivity: Results from the cervical dystonia patient registry for the observation of onabotulinumtoxinA efficacy. Mov Disord. 2015;30 Suppl 1:S516. 
• Parnes M, Robak L, Shulman JM, Stocco A, Jankovic J. Dystonia-spasticity in a patient with a novel SLC25A12 mutation. Mov Disord. 2015;30 Suppl 1:S480. 
• Wijemanne S, Jankovic J. Clinical utility of apraclonidine in ptosis. Mov Disord. 2015;30 Suppl 1:S204-5. 

American Academy of Neurology (AAN)
67^th Annual Meeting in Washington, DC (April 18-25, 2015)

• Comella C, Perlmutter J, Jinnah H, Factor S, Goetz C, Adler C, et al. Reliability of the severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2). Neurology. 2015;84(Meeting Abstracts 1):S15.001. [Oral Presentation] 
• Fernandez HH, Jankovic J, Holds J, Lin D, Burns J, Sethi K, et al. XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Final results from the blepharospasm cohort. Neurology. 2015;84(Meeting Abstracts 1):P4.331. 
• Molho E, Stacy M, Gillard P, Charles P, Adler C, Jankovic J, et al. The impact of cervical dystonia on work productivity: An analysis from the CD Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE). Neurology. 2015;84(Meeting Abstracts 1):P4.324. 
• Parnes M, Robak L, Shulman J, Stocco A, Jankovic J. Dystonia-spasticity in a patient with a novel SLC25A12 mutation. Neurology. 2015;84(Meeting Abstracts 1):P2.138.  [View poster]
• Wijemanne S, Jankovic J. SUNCT responding to botulinum toxin. Neurology. 2015;84(Meeting Abstracts 1):P3.049.  [View poster]

International Neurotoxin Association (INA)
Toxins 2017 2^nd International Conference in Lisbon, Portugal (Jan. 14-17, 2015)

• Comella C, Charles D, Jankovic J, Stacy M, Schwartz M, Manack Adams A, et al. Treatment patterns and patient disposition in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). Toxicon. 2015;93(Suppl):S17. 
• Jankovic J. Long-term effects of botulinum toxin injections. Toxicon. 2015;93(Suppl):S34. 

Movement Disorder Society (MDS)
18^th International Congress of Parkinson's Disease and Movement Disorders in Stockholm, Sweden (June 8-12, 2014)

• Charles D, Jankovic J, Adler CH, Comella C, Stacy M, Schwartz M, et al. Treatment patterns and patient disposition in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). Mov Disord. 2014;29 Suppl 1:1342. 
• Comella CL, Perlmutter JS, Jinnah HA, Factor S, Waliczek TA, Rosen AR, et al. Convergent validity of the revised motor and psychiatric TWSTRS modules of the Comprehensive Cervical Dystonia Rating Scale (CCDRS). Mov Disord. 2014;29 Suppl 1:1346. 
• Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, et al. Effectiveness and safety in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). Mov Disord. 2014;29 Suppl 1:1377. 
• Jimenez-Shahed J, York M, Smith-Gloyd EM, Jankovic J, Viswanathan A. MER vs. MRI guidance in placement of DBS electrodes for Parkinson's disease. Mov Disord. 2014;29 Suppl 1:1202.  [View poster]
• Vittal P, Pulliam CL, Goetz CG, Jankovic J, Ramirez-Castaneda JL, Heldman DA. Methodology for a symptomatic impact study using a portable essential tremor (ET) monitor to direct therapeutic interventions. Mov Disord. 2014;29 Suppl 1:1161. 
• Zurowski MJ, McDonald W, Comella CL, Perlmutter JS, Jinnah HA, Factor S, et al. Reliability and validity of the revised TWSTRS psychiatric module (TWSTRS-PSYCH) of the Comprehensive Cervical Dystonia Rating Scale (CCDRS). Mov Disord. 2014;29 Suppl 1:484. 

American Academy of Neurology (AAN)
66^th Annual Meeting in Philadelphia, Penn. (April 26 - May 3, 2014)

• Charles P, Jankovic J, Comella C, Stacy M, Schwartz M, Manack A, et al. Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Treatment patterns and subject disposition. Neurology. 2014;82(Meeting Abstracts 1):P7.062.  [View poster]
• Comella C, Perlmutter J, Jinnah H, Adler C, Barbano R, Factor S, et al. Clinimetric testing of the modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS). Neurology. 2014;82(Meeting Abstracts 1):S27.004. [Platform Presentation] 
• Jankovic J, Adler C, Charles P, Comella C, Stacy M, Schwartz M, et al. Treatment outcomes in Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). Neurology. 2014;82(Meeting Abstracts 1):P7.069.  [View poster]
• Patel N, Hanfelt J, Marsh L, Jankovic J. Alleviating maneuvers (sensory tricks) in cervical dystonia. Neurology. 2014;82(Meeting Abstracts 1):P2.046.  [View poster]
• Waln O, Wu Y, Perlman R, Van AK, Wendt J, Jankovic J. Dopamine transporter imaging in essential tremor with and without parkinsonian features. Neurology. 2014;82(Meeting Abstracts 1):S57.002. [Platform Presentation] 
• Wijemanne S, Jankovic J. Hereditary spastic paraplegia due to a novel mutation in SPG11 gene presenting as dopa responsive dystonia, parkinsonism and spasticity. Neurology. 2014;82(Meeting Abstracts 1):P4.057.  [View poster]

American Neurological Association (ANA)
138^th Annual Meeting in New Orleans, La. (Oct. 13-15, 2013)

• Pahwa R, Ellenbogen A, Kell S, O'Conell M, Hauser R, Fahn S, et al. Efficacy and safety of IPX066, a carbidopa-levodopa, extended-release formulation, in early Parkinson's disease. Ann Neurol. 2013;74 Suppl 17:S47. 

Movement Disorder Society (MDS)
17^th International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia (June 16-20, 2013)

• Baizabal-Carvallo JF, Kagnoff M, Jimenez-Shahed J, Fekete R, Jankovic J. The long-term safety and efficacy of thalamic deep brain stimulation in essential tremor. Mov Disord. 2013;28 Suppl 1:S430. 
• Hauser R, Surmann E, Rubin Z, Jankovic J. Minimal clinically important changes in UPDRS scores in early PD in rotigotine clinical trials. Mov Disord. 2013;28 Suppl 1:S170. 
• Heldman D, Pulliam C, Eichenseer S, Goetz C, Waln O, Hunter C, et al. Continuous home monitoring of essential tremor using motion sensors. Mov Disord. 2013;28 Suppl 1:S335. 
• Jankovic J, Charles D, Adler C, Comella C, Stacy M, Schwartz M, et al. Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy (CD PROBE): Baseline demographic and clinical characteristics. Mov Disord. 2013;28 Suppl 1:S31. 
• Patel N, Hanfelt J, Marsh L, Jankovic J, for the Dystonia Coalition. Sensory tricks (corrective maneuvers) in cervical dystonia. Mov Disord. 2013;28 Suppl 1:S7.  [View poster]
• Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost W, Kulisevsky J, et al. Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa (SETTLE). Mov Disord. 2013;28 Suppl 1:S152. 
• Taylor R, Baumann T, Marks Jr W, Ostrem J, Verhagen L, Stacy M, et al. Long-term safety of neurotrophic factor gene therapy using AAV2-neurturin (CERE-120) in Parkinson's disease. Mov Disord. 2013;28 Suppl 1:S40. 

American Academy of Neurology (AAN)
65^th Annual Meeting in San Diego, Calif. (March 16-23, 2013)

• Dhungana S, Jankovic J. Movement disorders in golfers. Neurology. 2013;80(Meeting Abstracts 1):P02.070.  [View poster]
• Fernandez H, Pagan F, Danisi F, Greeley D, Jankovic J, Verma A, et al. XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Interim results from the first 145 subjects with cervical dystonia. Neurology. 2013;80(Meeting Abstracts 1):P07.192. 
• Jankovic J, Charles P, Adler C, Comella C, Stacy M, Schwartz M, et al. Cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE): Baseline demographic and clinical characteristics. Neurology. 2013;80(Meeting Abstracts 1):P07.190. 
• Pulliam CL, Eichenseer S, Goetz C, Waln O, Hunter C, Jankovic J, et al. Continuous home monitoring of essential tremor using motion sensors. Neurology. 2013;80(Meeting Abstracts 1):P05.035. 
• Ramirez Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin injections in dystonia - a 20-year follow-up. Neurology. 2013;80(Meeting Abstracts 1):P07.197.  [View poster]
• Schapira A, Fox S, Hauser R, Jankovic J, Jost W, Kulisevsky J, et al. Safinamide add on to L-dopa: A randomized, placebo-controlled, 24-week global trial in patients with Parkinson's disease (PD) and motor fluctuations (SETTLE). Neurology. 2013;80(Meeting Abstracts 1):P01.062. 
• Waln O, Jankovic J. Zolpidem improves tardive dyskinesia with and without akathisia. Neurology. 2013;80(Meeting Abstracts 1):P07.205.  [View poster]
• Waln O, Wendt J, Van AK, Jankovic J. Clinical and imaging data in essential tremor with parkinsonian features. Neurology. 2013;80(Meeting Abstracts 1):P06.085.  [View poster]
• Wijemanne S, Jankovic J. The long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Neurology. 2013;80(Meeting Abstracts 1):P02.057.  [View poster]

International Neuropsychological Society (INS)
41^st Annual Meeting in Montreal, Waikoloa, Hawaii (Feb. 6-9, 2013)

• Wu TC, Wilde EA, Karmonik C, Yallampalli R, Strutt AM, Jankovic J, et al. Frontostriatal changes detected by DTI tractography in Parkinson's disease dementia. J Int Neuropsychol Soc. 2013;19(Suppl S1):250-1. 

Baylor College of Medicine (BCM)
Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012)

• Dhungana S, Jankovic J. Movement disorders in golfers - Four case reports and a brief review of literature. Presented at the Baylor College of Medicine (BCM), Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012).   [View poster]

American Neurological Association (ANA)
137^th Annual Meeting in Boston, Mass. (Oct. 7-9, 2012)

• Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on motor function in moderate Huntington disease. Ann Neurol. 2012;72 Suppl 16:S95. 
• Jankovic J, Thomas M, Vasquez A, Sethi KD, Verma A, Pappert EJ, et al. A prospective, observational trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia (CD) or blepharospasm in the United States - Preliminary baseline results on the health impact of CD on patients using the cervical dystonia impact profile (CDIP). Ann Neurol. 2012;72 Suppl 16:S102. 
• LeDoux MS, Jankovic J, Sethi KD, Verma A, Pappert EJ, Fernandez HH. A prospective, observational trial evaluating Xeomin [IncobotulinumtoxinA] for cervical dystonia or blepharospasm in the US - Preliminary baseline results for patients with blepharospasm. Ann Neurol. 2012;72 Suppl 16:S102-3. 
• Lee H-Y, Huang Y, Bruneau N, Roll P, Roberson EDO, Hermann M, et al. Mutations in the novel protein PRRT2 cause infantile convulsions with paroxysmal kinesigenic dyskinesia. Ann Neurol. 2012;72 Suppl 16:S59. 

Movement Disorder Society (MDS)
16^th International Congress of Parkinson's Disease and Movement Disorders in Dublin, Ireland (June 17-21, 2012)

• Baizabal Carvallo JF, Suresh K, Hunter C, Jankovic J. Flu-like and systemic symptoms following treatment with botulinum toxins. Mov Disord. 2012;27(Suppl 1):S422.  [View poster]
• Baumann T, Lang AE, Lozano AM, Olanow CW, Boulis N, Turner D, et al. AAV2-Neurturin (CERE-120) and Parkinson's disease: The safety and feasibility of combined substantia nigral and putaminal stereotactic targeting via a phase 1/2b clinical trial in advanced Parkinson's disease. Presented at the Movement Disorder Society (MDS), 16^th International Congress of Parkinson's Disease and Movement Disorders in Dublin, Ireland (June 17-21, 2012).   [View poster]
• Charles PD, Stacy M, Jankovic J, Schwartz M, Brin M, Papapetropoulos S (on behalf of the CD PROBE Study Group). Cervical dystonia subtypes baseline results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). Mov Disord. 2012;27(Suppl 1):S335.  [View poster]
• Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on motor function in moderate Huntington's disease. Mov Disord. 2012;27(Suppl 1):S54. 
• Jankovic J, Thomas M, Vasquez A, Sethi K, Verma A, Pappert EJ, et al. XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia (CD) or blepharospasm in the United States - Preliminary baseline results on the health impact of CD on patients using the cervical dystonia impact profile. Mov Disord. 2012;27(Suppl 1):S344. 
• LeDoux MS, Jankovic J, Sethi K, Verma A, Pappert EJ, Fernandez HH. XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm in the United States - Preliminary baseline results for patients with blepharospasm. Mov Disord. 2012;27(Suppl 1):S348-9. 
• Mehanna R, Hunter C, Davidson A, Ondo W, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2012;27(Suppl 1):S457.  [View poster]
• Ondo WG, Jankovic J, Jimenez-Shahed J. Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Mov Disord. 2012;27(Suppl 1):S404. 
• Pan T, Wu Y, Zhu JX, Jankovic J. Neuroprotection by neuropeptide orexin A in a cellular model of Parkinson's disease. Mov Disord. 2012;27(Suppl 1):S48. 
• Sanghera MK, Darbin O, Alam M, Friehs J, Friehs G, Jankovic J, et al. Entropy measurements in pallidal neurons in dystonia and Parkinson disease. Mov Disord. 2012;27(Suppl 1):S212-3.  [View poster]
• Shen V, Clarence-Smith K, Hunter C, Jankovic J. Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease. Mov Disord. 2012;27(Suppl 1):S59-60.  [View poster]
• Shen V, Clarence-Smith K, Hunter C, Jankovic J. Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease. Mov Disord. 2012;27(Suppl 1):S60.  [View poster]
• Shen V, Clarence-Smith K, Hunter C, Jankovic J. Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease. Mov Disord. 2012;27(Suppl 1):S60.  [View poster]
• Zhang Z, Xie W, Hintermann S, Jankovic J, Le W. Anti-parkinsonian effects of Nurr1 activator in UPS impairment induced animal model of Parkinson's disease. Mov Disord. 2012;27(Suppl 1):S43. 

American Academy of Neurology (AAN)
64^th Annual Meeting in New Orleans, La. (April 21-28, 2012)

• Baizabal Carvallo J, Jankovic J. Flu-like and systemic symptoms following treatment with botulinum toxins. Neurology. 2012;78(Meeting Abstracts 1):P01.230.  [View poster]
• Charles P, Jankovic J, Adler C, Brin M, Stacy M, Schwartz M, et al. Severity of cervical dystonia: Baseline characteristics from the Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CDPROBE). Neurology. 2012;78(Meeting Abstracts 1):P01.231. 
• Clarence-Smith K, Shen V, Hunter C, Jankovic J. Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease (HD). Neurology. 2012;78(Meeting Abstracts 1):P06.039.  [View poster]
• Evidente VG, Brodsky M, Gollomp S, Marx M, Hanschmann A, Jankovic J. IncobotulinumtoxinA (Xeomin®) is well tolerated for the treatment of blepharospasm when injected according to patient needs. Neurology. 2012;78(Meeting Abstracts 1):PD4.010. 
• Killoran A, Biglan K, Jankovic J, Eberly S, Kayson E, Oakes D, et al. Analysis of the behavioral features conferred by the intermediate allele for Huntington disease in the prospective Huntington at risk observational study (PHAROS). Neurology. 2012;78(Meeting Abstracts 1):PL01.003. 
• LeDoux M, Lin D, Jankovic J, Pappert E, Verma A, Sethi K, et al. XCiDaBLE: A phase 4, observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Preliminary baseline disease severity and quality of life data. Neurology. 2012;78(Meeting Abstracts 1):P01.240. 
• Mehanna R, Jankovic J. Dystonic respiratory dysregulation and other breathing disorders associated with dystonia. Neurology. 2012;78(Meeting Abstracts 1):P01.223.  [View poster]
• Scharf J, Yu D, Mathews C, Neale B, Stewart E, Fagerness J, et al. Genome-wide association study of Gilles de la Tourette Syndrome. Neurology. 2012;78(Meeting Abstracts 1):S32.006. 
• Shen V, Clarence-Smith K, Hunter C, Jankovic J. Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease. Neurology. 2012;78(Meeting Abstracts 1):P06.034.  [View poster]
• Shen V, Clarence-Smith K, Hunter C, Jankovic J. Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease (HD). Neurology. 2012;78(Meeting Abstracts 1):P06.032.  [View poster]
• Waln O, Jimenez Shahed J, Juliet Wendt, York M, Baizabal Carvallo J, Mehanna R, et al. Diagnostic reliability of DaTscan in movement disorders. Neurology. 2012;78(Meeting Abstracts 1):P03.125.  [View poster]

Society for Neuroscience (SFN)
41^st Annual Meeting in Washington, DC (Nov. 12-16, 2011)

• Red S, Ing J, Jeter CB, Hood AJ, Patel SS, Jankovic J, et al. Horizontal and vertical eye movements in Huntington's disease patients and age matched controls. Program No. 148.18. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online. 

American Neurological Association (ANA)
136^th Annual Meeting in San Diego, Calif. (Sept. 25-27, 2011)

• Litvan I, Cunningham CR, Lees P, Jackson L, Juncos J, Riley D, et al. Association of PSP with chemical occupational exposure factors. Ann Neurol. 2011;70 Suppl 15:S16-7. 

European Federation of Neurological Societies (EFNS)
15^th Congress in Budapest, Hungary (Sept. 10-13, 2011)

• Truong DD, Brodsky MA, LeWitt PA, Gollomp SM, Kanovsky P, Pulte I, et al. Sustained efficacy of long-term incobotulinumtoxin-a (Xeomin®; botulinum neurotoxin type-a, free from accessory proteins) treatment for cervical dystonia, blepharospasm and upper limb post-stroke spasticity. Eur J Neurol. 2011;18 (Suppl 2):501. 

Movement Disorder Society (MDS)
15^th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada (June 5-9, 2011)

• Baizabal Carvallo JF, Mostile G, Almaguer M, Davidson A, Simpson R, Jankovic J. Deep brain stimulation: Hardware related complications in patients with movement disorders. Mov Disord. 2011;26 Suppl 2:S84-5.  [View poster]
• Boroojerdi B, Watts RL, Jankovic J, Surmann E, Ghys L. The long-term impact of early versus delayed treatment with rotigotine transdermal system in patients with early-stage, idiopathic Parkinson's disease. Mov Disord. 2011;26 Suppl 2:S121.  [View poster]
• Brodsky M, Jankovic J, Evidente VGH, Fernandez HH, Grafe SK. IncobotulinumtoxinA (NT-201) injections are safe and effective in adult subjects with blepharospasm across dosing intervals in a repeated dose-study. Mov Disord. 2011;26 Suppl 2:S206.  [View poster]
• Brown CH, Ha AD, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Mov Disord. 2011;26 Suppl 2:S170.  [View poster]
• Charles PD, Jankovic J, Stacy M, Adler CH, Comella C, Brin M, et al. Correlation of patient impression with the cervical dystonia impact questionnaire. Mov Disord. 2011;26 Suppl 2:S207. 
• Fekete R, Baizabal-Carvallo JF, Ha AD, Jankovic J. Convergence spasm in conversion disorders: Prevalence in psychogenic and other movement disorders compared to controls. Mov Disord. 2011;26 Suppl 2:S357.  [View poster]
• Gallo BV, Okun MS, Mandybur G, Arle J, Elias J, Ford B, et al. Constant current DBS: A randomized controlled clinical trial in Parkinson's disease: 12 month results. Mov Disord. 2011;26 Suppl 2:S128. 
• Heldman DA, Filipkowski D, Jankovic J, Vaillancourt D, Prodoehl J, Elble RJ, et al. Essential tremor quantification during activities of daily living. Mov Disord. 2011;26 Suppl 2:S377. 
• Hen X, Li L, Zhang X, Jankovic J, Le W. Identification of a novel downstream target of Nurr1 transcription factor for midbrain dopamine neuron development. Mov Disord. 2011;26 Suppl 2:S20-1. 
• Jankovic J, Stacy M, Charles PD, Adler CH, Comella C, Brin M, et al. Cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE): Study design of a prospective observational registry. Mov Disord. 2011;26 Suppl 2:S215.  [View poster]
• Li X, Xie W, Jankovic J, Le W. A mechanistic study of proteasome inhibition-induced iron misregulation in dopaminergic neuron degeneration. Mov Disord. 2011;26 Suppl 2:S20.  [View poster]
• Mostile G, Fekete R, Giuffrida JP, Yaltho T, Davidson A, Nicoletti A, et al. Amplitude fluctuations in essential tremor. A prospective study. Mov Disord. 2011;26 Suppl 2:S380.  [View poster]
• Okun MS, Gallo BV, Mandybur G, Arle J, Elias J, Ford B, et al. A randomized controlled trial of constant current DBS active stimulation versus off stimulation in Parkinson's disease. Mov Disord. 2011;26 Suppl 2:S76-7. 
• Pahwa R, Ellenbogen A, Jankovic J, Hauser R, Fahn S, Clinical Team at Impax Pharmaceuticals. Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naive early Parkinson's disease (APEX-PD trial). Mov Disord. 2011;26 Suppl 2:S137. 
• Palao AM, Hunter CB, Jankovic J. Patients' perspective of tetrabenazine two years after FDA approval. Mov Disord. 2011;26 Suppl 2:S259.  [View poster]
• Pan T, Zhu J, Li X, Jankovic J. Alpha-synuclein: Possible link between Parkinson's disease and melanoma. Mov Disord. 2011;26 Suppl 2:S24.  [View poster]
• Squitieri F, Esmaeilzadeh M, Ciarmiello A, Jankovic J. Brain glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG33 repeat length in the Huntington's disease gene. Mov Disord. 2011;26 Suppl 2:S64. 
• Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Tilley BC. Postural instability and gait difficulty scores from the MDS-UPDRS. Mov Disord. 2011;26 Suppl 2:S358. 
• Strutt AM, Scott BM, Ferrara J, York MK, Jankovic J. Assessing dissociative pathology in psychogenic movement disorders: Clinical utility of the Dissociative Experiences Scale-II. Mov Disord. 2011;26 Suppl 2:S266.  [View poster]
• Tagliati M, Gallo BV, Mandybur G, Arle J, Elias J, Ford B, et al. Safety data in a randomized controlled trial of constant current deep brain stimulation versus lead placement alone for treatment of motor fluctuations in Parkinson's disease. Mov Disord. 2011;26 Suppl 2:S142-3. 
• van Rooijen DE, Geraedts EJ, Marinus J, Jankovic J, van Hilten JJ. Peripheral trauma and movement disorders: A systematic review of reported cases. Mov Disord. 2011;26 Suppl 2:S231-2. 

American Academy of Neurology (AAN)
63^rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)

• Baizabal Carvallo JF, Mostile G, Simpson R, Almaguer M, Davidson A, Jankovic J. Deep brain stimulation system revision, and hardware related complications in 512 patients with movement disorders. Neurology. 2011;76(Suppl 4):A450.  [View platform presentation]
• Charles P, Adler CH, Stacy M, Comella C, Jankovic J, Boo LM, et al. Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of pain-related outcomes. Neurology. 2011;76(Suppl 4):A331.  [View poster]
• Evidente VG, Truong D, Fernandez H, Comella C, Brodsky M, Jankovic J, et al. Efficacy and safety of repeated incobotulinumtoxin A injections in subjects with cervical dystonia previously treated with botulinum toxin. Neurology. 2011;76(Suppl 4):A540-1. 
• Fernandez H, Comella C, Brodsky M, Evidente VG, Jankovic J, Truong D, et al. Efficacy and safety of repeated incobotulinumtoxin A injections in subjects with cervical dystonia previously naive to botulinum toxin treatment. Neurology. 2011;76(Suppl 4):A330. 
• Ha AD, Davidson A, Jankovic J. Intermediate CAG repeats: Analysis of the cooperative Huntington's observational research trial. Neurology. 2011;76(Suppl 4):A549.  [View platform presentation]
• Heldman D, Filipkowski D, Jankovic J, Vaillancourt D, Prodoehl J, Elble R, et al. Essential tremor quantification during activities of daily living. Neurology. 2011;76(Suppl 4):A125. 
• Jankovic J, Charles P, Adler CH, Stacy M, Comella C, Boo LM, et al. Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of physician-reported outcomes. Neurology. 2011;76(Suppl 4):A330.  [View poster]
• Pahwa R, Hauser R, Jankovic J, Nausieda P, Ellenbough A, Hsu A, et al. Double-blind, placebo-controlled fixed-dose trial of IPX066, a novel carbidopa-levodopa (CD-LD) extended-release formulation, in early Parkinson's disease (APEX-PD). Presented at the American Academy of Neurology (AAN), 63^rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011).  
• Pan T, Li X, Zhu J, Le W, Jankovic J. AMPK-mediated neuroprotection on cellular models of Parkinson's disease. Neurology. 2011;76(Suppl 4):A276.  [View poster]
• Stacy M, Charles P, Adler CH, Comella C, Jankovic J, Boo LM, et al. Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of patient-reported outcomes. Neurology. 2011;76(Suppl 4):A331.  [View poster]
• Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Tilley BC. Postural instability and gait difficulty scores from the MDS-UPDRS. Neurology. 2011;76(Suppl 4):A586. 
• Strutt AM, Scott BM, Ferrara JM, York MK, Jankovic J. Psychosocial profiles of psychogenic movement disorder patients with non-epileptic seizures and other abnormal motor manifestations. Neurology. 2011;76(Suppl 4):A591.  [View poster]
• York M, Yallampalli R, Gallander K, Strutt A, Chu Z, Karmonik C, et al. Diffusion tensor tractography of the internal capsule in depressed and anxious Parkinson's disease patients. Neurology. 2011;76(Suppl 4):A490.  [View poster]

AD/PD
10^th International Congress on Alzheimer's and Parkinson's Diseases in Barcelona, Spain (March 9-13, 2011)

• York M, Yallampalli R, Gallander K, Strutt A, Chu Z, Karmonik C, et al. Diffusion tensor tractography of the internal capsule differentiates stages of cognitive impairment in Parkinson's disease. Presented at the AD/PD, 10^th International Congress on Alzheimer's and Parkinson's Diseases in Barcelona, Spain (March 9-13, 2011).   [View poster]

Movement Disorder Society (MDS)
14^th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010)

• Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, et al. Longitudinal analysis of intermediate CAGn repeat length expansion in the prospective Huntington's disease at-risk observational study (PHAROS). Mov Disord. 2010;25 Suppl 2:S270.  [View poster]
• Charles D, Adler C, Comella C, Jankovic J, Stacy M, Kurth M, et al. CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) — preliminary safety data. Mov Disord. 2010;25 Suppl 2:S232.  [View poster]
• Davidson AL, Hunter C, Jankovic J. Validation of a cervical dystonia questionnaire (CDQ). Mov Disord. 2010;25 Suppl 2:S233.  [View poster]
• Gilman S, Low P, May S, Tanner C, Stern M, Sandroni P, et al. Prospective 5-year natural history study of probable multiple system atrophy (MSA) in 175 North American subjects. Mov Disord. 2010;25 Suppl 2:S498-9.  [View poster]
• Grafe S, Hanschmann A, Jankovic J, Comella C. Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with blepharospasm. Mov Disord. 2010;25 Suppl 2:S235-6.  [View poster]
• Hunter CB, York MK, Jankovic J. Validation of a motor screen for undiagnosed parkinsonism: The Baylor Functional Assessment Screen (BFAS). Mov Disord. 2010;25 Suppl 2:S349.  [View poster]
• Kurth M, Adler C, Comella C, Charles D, Jankovic J, Stacy M, et al. CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) — CD impact on quality of life (QOL) and patient reported outcomes (PRO). Mov Disord. 2010;25 Suppl 2:S229-30.  [View poster]
• Li C, Xie W, Jankovic J, Le W. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Mov Disord. 2010;25 Suppl 2:S403.  [View poster]
• Marx M, Grafe S, Jankovic J, Comella C. Use of an interactive voice response system by patients with blepharospasm receiving repeated injections of NT 201 (botulinum neurotoxin type A free from complexing proteins). Mov Disord. 2010;25 Suppl 2:S243.  [View poster]
• Palao AM, Mostile G, Hunter CB, Jankovic J. Assessing patients' access to tetrabenazine (Xenazine) after FDA approval. Mov Disord. 2010;25 Suppl 2:S275.  [View poster]
• Pan T, Wu Y, Le W, Jankovic J. Curcumin accelerates the clearance of mutant alpha-synuclein and injured mitochondria via autophagy induction. Mov Disord. 2010;25 Suppl 2:S506.  [View poster]
• Schapira AHV, Fox S, Hauser R, Jankovic J, Kulisevsky J, Pahwa R, et al. SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases. Mov Disord. 2010;25 Suppl 2:S308-9.  [View poster]
• Strutt AM, Scott BM, Yaltho T, Simpson R, Jankovic J, York MK. Neuropsychological assessment of monolingual Spanish speaking Parkinson's disease patients in the United States pre and post STN-DBS. Mov Disord. 2010;25 Suppl 2:S327.  [View poster]
• Watts RL, Boroojerdi B, Jankovic J, on behalf of the SP702 Study Group. Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: Results from up to 7 years. Mov Disord. 2010;25 Suppl 2:S310-1.  [View poster]
• Wu Y, Almaguer MA, Atassi F, Lai EC, Jankovic J, Ondo WG. Retrospective study of the therapeutic effect of deep brain stimulation in multiple system atrophy. Mov Disord. 2010;25 Suppl 2:S505.  [View poster]
• Yaltho TC, Jankovic J, Ondo WG. Orthostatic tremor: A review of 40 cases. Mov Disord. 2010;25 Suppl 2:S538.  [View poster]

American Academy of Neurology (AAN)
62^nd Annual Meeting in Toronto, Canada (April 10-17, 2010)

• Fekete R, Jankovic J. Upper face chorea in Huntington disease. Neurology. 2010;74(9 Suppl 2):A414.  [View poster]
• Ferrara J, Mostile G, Hunter C, Adam O, Jankovic J. Effect of tetrabenazine (TBZ) on motor function in patients with Huntington disease (HD). Neurology. 2010;74(9 Suppl 2):A412.  [View poster]
• Jankovic J, Adler C, Charles D, Comella C, Stacy M, Kurth M, et al. CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) — A multicenter, observational study of onabotulinumtoxin A injections in cervical dystonia (CD) patients — Interim patient reported outcome data. Neurology. 2010;74(9 Suppl 2):A89.  [View poster]
• Jankovic J, Adler C, Charles D, Comella C, Stacy M, Kurth M, et al. CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) — A multicenter, observational study of repeated onabotulinumtoxin A injections in cervical dystonia (CD) patients — Preliminary baseline data. Neurology. 2010;74(9 Suppl 2):A85-6.  [View poster]
• Jeter C, Hood A, Palao A, Patel S, Jankovic J, Sereno A. Clinical correlates of eye movements in Huntington disease. Neurology. 2010;74(9 Suppl 2):A413.  [View poster]
• Li X, Li C, Xie W, Jankovic J, Le W. Ubiquitin proteasome system impairment mouse model of Parkinson's disease. Neurology. 2010;74(9 Suppl 2):A82.  [View poster]
• Pan T, Wu Y, Xie W, Le W, Jankovic J. HIF-1α-mediated neuroprotection on MPP+-induced apoptosis in SH-SY5Y cells. Neurology. 2010;74(9 Suppl 2):A443.  [View poster]
• Rascol O, for the ADAGIO investigators. The natural progression of clinical symptoms in Parkinson's disease may not be faster in the earlier stages: Results from the ADAGIO delayed-start study. Neurology. 2010;74(9 Suppl 2):A317.  [View poster]
• Watts R, Boroojerdi B, Jankovic J, on behalf of the SP702 Study Group. Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: Results from up to seven years. Neurology. 2010;74(9 Suppl 2):A351.  [View poster]
• Wu Y, Davidson A, Huang M, Pan T, Jankovic J. Asian over representation among patients with hemifacial spasm compared to cranial dystonia. Neurology. 2010;74(9 Suppl 2):A90.  [View poster]
• York M, Karmonik C, Burton P, Richards D, Kakkar E, Grossman R, et al. A novel set shifting fMRI task identifies differences in brain activation in Parkinson's disease and healthy controls. Neurology. 2010;74(9 Suppl 2):A248.  [View poster]

World Federation of Neurology (WFN)
XVIII World Congress on Parkinson's Disease and Related Disorders in Miami Beach, Fla. (Dec. 13-16, 2009)

• Jankovic J, ADAGIO Investigators. Rasagiline provides symptomatic benefit in early Parkinson's disease (PD). Parkinsonism Relat Disord. 2009;15(Suppl 2):S127-8. 
• Marks Jr W, Bartus R, Siffert J, Starr P, Ostrem J, Stacy M, et al. Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD). Parkinsonism Relat Disord. 2009;15(Suppl 2):S120. 
• Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S224-32. 

Baylor College of Medicine (BCM)
Current Neurology 2009 in Houston, Texas (Oct. 31 - Nov. 1, 2009)

• Gallander KM, Strutt AM, Simpson R, Jankovic J, York MK. Influence of levodopa and psychotropic medication on emotional and physical symptoms of depression before and following STN-DBS for the treatment of Parkinson's disease. Presented at the Baylor College of Medicine (BCM), Current Neurology 2009 in Houston, Texas (Oct. 31 - Nov. 1, 2009).   [View poster]
• Marshall DF, Williams AE, Strutt AM, Jankovic J, York MK. Alternating fluency performance following bilateral STN DBS for the treatment of Parkinson's disease. Presented at the Baylor College of Medicine (BCM), Current Neurology 2009 in Houston, Texas (Oct. 31 - Nov. 1, 2009).   [View poster]

Society for Neuroscience (SFN)
39^th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2009)

• Siffert J, Marks Jr WJ, Starr PA, Stacey MA, Boulis NM, Vitek JL, et al. AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD): Efficacy and safety results from a controlled Phase 2 clinical trial. Program No. 326.7. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online. 

Movement Disorder Society (MDS)
13^th International Congress of Parkinson's Disease and Movement Disorders in Paris, France (June 7-11, 2009)

• DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Long-term deep brain stimulation for essential tremor: 12- year clinicopathologic follow up and literature review. Mov Disord. 2009;24 Suppl 1:S482-3.  [View poster]
• Ferrara FM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Double-blind, randomized, placebo-controlled, cross-over trial of pregabalin in essential tremor. Mov Disord. 2009;24 Suppl 1:S508.  [View poster]
• Ferrara JM, Diamond A, Davidson A , Almaguer M, Jankovic J. Impact of STN-DBS on health-related quality of life in patients with Parkinson's disease. Mov Disord. 2009;24 Suppl 1:S368.  [View poster]
• Gelineau-Kattner RN, Jankovic J, Davidson AL. Tourette syndrome in adults. Mov Disord. 2009;24 Suppl 1:S496.  [View poster]
• Grafe S, Comella C, Jankovic J, Truong D, Hanschmann A. Efficacy and safety of NT 201 (botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients. Mov Disord. 2009;24 Suppl 1:S92-3. 
• Grafe S, Comella C, Jankovic J, Truong D, Hanschmann A. Efficacy and safety of NT 201, botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients. Mov Disord. 2009;24 Suppl 1:S92. 
• Jankovic J, Jimenez-Shahed J, Brown LW. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Mov Disord. 2009;24 Suppl 1:S497.  [View poster]
• Le W, Nguyen D, Lin W, Rawal P, Ding Y, Xie W, et al. Transcription factor PITX3 in Parkinson's disease. Mov Disord. 2009;24 Suppl 1:S143.  [View poster]
• Mostile G, Giuffrida JP, A dam OR, Davidson A, Jankovic J. Correlation between Kinesia system assessments and clinical TETRAS scores in patients with essential tremor. Mov Disord. 2009;24 Suppl 1:S510-1.  [View poster]
• Pan T, Xie W, Jankovic J, Le W. 17-AAG protects against rotenone-induced apoptosis in SHSY5Y cells via HSP70 induction. Mov Disord. 2009;24 Suppl 1:S361.  [View poster]
• Pan T, Xie W, Le W, Jankovic J. Resveratrol, a polyphenol found in red wine, protects against rotenone-induced apoptosis through autophagy induction. Mov Disord. 2009;24 Suppl 1:S225-6.  [View poster]
• Ravina B, Elm J, Camicioli R, Como P, Marsh L, Jankovic J, et al. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009;24 Suppl 1:S249. 
• Strutt AM, Ferrara J, Hill S, York MK, Uber-Zak L, Fogel T, et al. Mood differences between women diagnosed with psychogenic movement disorders and psychogenic seizures. Mov Disord. 2009;24 Suppl 1:S232-3.  [View poster]

American Academy of Neurology (AAN)
61^st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)

• Adam O, Halton S, Mostile G, Jankovic J. The written and oral administration of the Symbol Digit Modality Test in Huntington disease. Neurology. 2009;72(11 Suppl 3):A448.  [View poster]
• Comella C, Jankovic J, Truong D, Hanschmann A, Grafe S. Efficacy and safety of NT 201 (neurotoxin free from complexing proteins) in cervical dystonia. Neurology. 2009;72(11 Suppl 3):A345.  [View poster]
• Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of NT 201 (botulinum neurotoxin free from complexing proteins) in blepharospasm. Neurology. 2009;72(11 Suppl 3):A346.  [View poster]
• Pan T, Xie W, Rawal P, Jankovic J, Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction in SH-SY5Y cells. Neurology. 2009;72(11 Suppl 3):A438-9.  [View platform presentation]
• Williams A, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK. A controlled study of the long-term cognitive outcome of bilateral subthalamic nucleus deep brain stimulation. Neurology. 2009;72(11 Suppl 3):A221.  [View poster]

6^th International Congress on Mental Dysfunctions and Other Non-Motor Features in Parkinson's Disease and Related Disorders
Dresden, Germany (Oct. 16-19, 2008)

• York M, Karmonik C, Wilde E, Kakkar E, Yallampalli R, Strutt A, et al. Voxel-based diffusion tensor imaging and diffusion tensor tractography for the evaluation of cognitive functioning in Parkinson's disease. Presented at the 6^th International Congress on Mental Dysfunctions and Other Non-Motor Features in Parkinson's Disease and Related Disorders, Dresden, Germany (Oct. 16-19, 2008).   [View poster]

American Neurological Association (ANA)
133^rd Annual Meeting in Salt Lake City, Utah (Sept. 21-24, 2008)

• Xie W, Zhu W, Pan T, Jankovic J, Le W. Progressive DA neuron degeneration induced by targeting administration of proteasome inhibitor in SN. Ann Neurol. 2008;64 Suppl 12:S46-7. 

Movement Disorder Society (MDS)
12^th International Congress of Parkinson's Disease and Movement Disorders in Chicago, Ill. (June 22-26, 2008)

• Adam OR, Jankovic J. Unusual motor-phonic tic mimicking essential palatal myoclonus (EPM). Mov Disord. 2008;23 Suppl 1:S147.  [View poster]
• Aguilar LG, Giuffrida JP, Heldman DD, Jankovic J. Correlation between clinical rating of parkinsonian and essential tremor and quantitative assessments. Mov Disord. 2008;23 Suppl 1:S300.  [View poster]
• Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos J, et al. The essential tremor rating assessment scale (TETRAS). Mov Disord. 2008;23 Suppl 1:S357.  [View poster]
• Gupta A, Jankovic J. Spinocerebellar Ataxia 8: Variable phenotype and unique pathogenesis. Mov Disord. 2008;23 Suppl 1:S150.  [View poster]
• Hunter CB, Aguilar LG, Nashatizadeh MM, Lay LF, Jankovic J. Evaluation of a Parkinson's disease screening questionnaire for use in a community-based setting. Mov Disord. 2008;23 Suppl 1:S361.  [View poster]
• Jimenez-Shahed J, Baker K, Davidson A, Jankovic J. The role of dopaminergic medication doses in impulse control disorders (ICD) in Parkinson's disease (PD). Mov Disord. 2008;23 Suppl 1:S82.  [View poster]
• Le WD, Pan T, Xie W, Huang M, Xu P, Zhu W, et al. Expanded study of NURR1 gene expression in patients with Parkinson's disease. Mov Disord. 2008;23 Suppl 1:S36.  [View poster]
• Nashatizadeh MM, Jankovic J. Deep brain stimulation of the subthalamic nucleus for peripherally-induced parkinsonism. Mov Disord. 2008;23 Suppl 1:S135.  [View poster]
• Nashatizadeh MM, Jimenez JE, Davidson AL, Jankovic J. A randomized, double-blind, placebo-controlled study of atomoxetine for freezing of gait in Parkinson's disease. Mov Disord. 2008;23 Suppl 1:S219.  [View poster]
• Pan T, Xie W, Jankovic J, Le WD. Rapamycin rescues lactacystin-induced dopaminergic neuron injury in vivo. Mov Disord. 2008;23 Suppl 1:S23.  [View poster]
• Strutt AM, Jankovic J, York MK. Neuropsychological functioning of Parkinson's disease patients two years post subthalamic nucleus deep brain stimulation surgery. Mov Disord. 2008;23 Suppl 1:S106.  [View poster]
• Tagliati M, Jankovic J, Koss AM, Pagan F, Okun MS, National Parkinson Foundation DBS Working Group. Experience with MRI safety and DBS: Data from the National Parkinson Foundation Centers of Excellence. Mov Disord. 2008;23 Suppl 1:S110.  [View poster]

American Academy of Neurology (AAN)
60^th Annual Meeting in Chicago, Ill. (April 12-19, 2008)

• Adam OR, Aguilar Tabora LG, Ferrara J, Nashatizadeh M, Jankovic J. Volume and nature of patient telephone calls in a large movement disorders center. Neurology. 2008;70(11 Suppl 1):A120-1.  [View platform presentation]
• Aguilar Tabora LG, Davidson A, Jankovic J, Ondo WG. Characteristics of Archimedean spiral drawing in patients with psychogenic tremor. Neurology. 2008;70(11 Suppl 1):A390-1.  [View poster]
• Ferrara JM, Jankovic J. Morbidity associated with psychogenic movement disorders in children. Neurology. 2008;70(11 Suppl 1):A391.  [View poster]
• Ferrara JM, Jankovic J. Phenomenology of psychogenic movement disorders in children. Neurology. 2008;70(11 Suppl 1):A391.  [View poster]
• Goetz CG, Tilley BC, Shaftman SR, Fahn S, Martinez-Martin P, Poewe W, et al. New version of the UPDRS (MDS-UPDRS): Factor analysis. Neurology. 2008;70(11 Suppl 1):A55-6. 
• Jimenez-Shahed J, Calhoun K, Davidson A, Jankovic J. Craving for sweets and other compulsive behaviors in patients with Parkinson's disease. Neurology. 2008;70(11 Suppl 1):A288-9.  [View poster]
• Jimenez-Shahed J, Hunter CB, Jankovic J. Acamprosate improves impulse control disorders in Parkinson's disease. Neurology. 2008;70(11 Suppl 1):A288.  [View poster]
• Nashatizadeh M, Jankovic J. Treatment of freezing of gait in Parkinson's disease with deep brain stimulation of the pedunculopontine nucleus. Neurology. 2008;70(11 Suppl 1):A388-9.  [View poster]
• Pan T, Li X, Xie W, Jankovic J, Le WD. Role of deferoxamine and autophagy induction in rotenone-induced apoptosis. Neurology. 2008;70(11 Suppl 1):A325-7.  [View poster]
• Strutt AM, York MK, Jankovic J . Changes in emotional versus physical symptoms of depression following sub-thalamic nucleus deep brain stimulation for Parkinson's disease. Neurology. 2008;70(11 Suppl 1):A177-8.  [View poster]
• Wijemanne S, Jankovic J. Hemidystonia-hemiatrophy syndrome. Neurology. 2008;70(11 Suppl 1):A432-3. 

Movement Disorder Society (MDS)
11^th International Congress of Parkinson's Disease and Movement Disorders in Istanbul, Turkey (June 3-7, 2007)

• Chaudhuri KR, Jankovic J, Trenkwalder C, Boroojerdi B. Rotigotine transdermal patch as a treatment of nocturnal symptoms in patients with idiopathic Parkinson's disease. Mov Disord. 2007;22 Suppl 16:S196. 
• Goetz CG, Tilley BC, Shaftman S, Stebbins GT, Fahn S, Martinez-Martin P, et al. Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version. Mov Disord. 2007;22 Suppl 16:S6. 
• Hall DA, Ringel S, Howard K, Jankovic J. Clinical features of movement disorders in hemochromatosis. Mov Disord. 2007;22 Suppl 16:S129. 
• Kenney C, Barbano R, Sheffield KJ, Jankovic J. Deep brain stimulation for tardive dyskinesia and akathisia. Mov Disord. 2007;22 Suppl 16:S111.  [View poster]
• Kenney C, Diamond AL, Davidson A, Shinawi LM, Jankovic J. Health related quality of life in essential tremor patients undergoing deep brain stimulation. Mov Disord. 2007;22 Suppl 16:S287-8.  [View poster]
• Kenney C, Diamond AL, Davidson A, Shinawi LM, Jankovic J. Health related quality of life in Parkinson's disease patients undergoing deep brain stimulation. Mov Disord. 2007;22 Suppl 16:S85-6.  [View poster]
• LeWitt PA, Patton JM, MacMahon DG, Jankovic J. Switch from an oral dopamine agonist to rotigotine transdermal patch in Parkinson's disease. Mov Disord. 2007;22 Suppl 16:S104. 
• Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. Motor and behavioral outcomes after bilateral GPi deep brain stimulation for severe Tourette syndrome. Mov Disord. 2007;22 Suppl 16:S283. 
• Stamey W, Jankovic J . Shoulder pain in Parkinson's disease. Mov Disord. 2007;22 Suppl 16:S246-7.  [View poster]
• Stamey W, Jankovic J . The other Babinski sign in hemifacial spasm. Mov Disord. 2007;22 Suppl 16:S210-1.  [View poster]
• Wu J, Sitburana O, Jankovic J. The specificity and sensitivity of "applause sign" in differentiating PSP and other parkinsonian syndromes. Mov Disord. 2007;22 Suppl 16:S253-4. 
• Zhu W, Pan T, Xie W, Jankovic J, Zheng H, Youdim M, et al. Brain permeable iron chelators M-30 and AK-28 rescue degenerated nigral dopamine neurons in animal model of PD. Mov Disord. 2007;22 Suppl 16:S201.  [View poster]

American Academy of Neurology (AAN)
59^th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)

• Cheung MC, Shahed J, Jankovic J. Malignant Tourette syndrome. Neurology. 2007;68(12 Suppl 1):A155. 
• Deng H, Le W, Shahed J, Jankovic J. Three parkin mutations in a family with Parkinson's disease. Neurology. 2007;68(12 Suppl 1):A323. 
• Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington disease with 29 trinucleotide repeats. Neurology. 2007;68(12 Suppl 1):A228. [Previously Presented]  [View poster]
• Pan T, Li X, Zhu W, Xie W, Jankovic J, Le W. Autophagy induction and its neuroprotection on neurotoxin-induced cell injury relevant to Parkinson's disease. Neurology. 2007;68(12 Suppl 1):A111. 
• Sitburana O, Wu LJC, Sheffield KJ, Davidson A, Jankovic J. Motor overflow, contralateral dystonia and mirror movements in focal hand dystonia. Neurology. 2007;68(12 Suppl 1):A115.  [View poster]
• Tanner C, Kukrull W, Shults C, Comyns K, Bhudhikanok G, May S, et al. Head injury with amnesia and risk of multiple system atrophy (MSA). Neurology. 2007;68(12 Suppl 1):A49-50. 
• Zhu W, Pan T, Xie W, Xu P, Zheng H, Fridkin M, et al. Novel brain permeable iron chelators prevent lactacystin induced ubiquitin-proteasome inhibition and degeneration of nigrostriatal dopamine neurons. Neurology. 2007;68(12 Suppl 1):A113. 
• Zhu W, Pan T, Zhang X, Xie W, Jankovic J, Le W. Proteasome inhibition in substantial nigra induces sustained dopamine cells degeneration. Neurology. 2007;68(12 Suppl 1):A111. 

8^th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Salzburg, Austria (March 14-18, 2007)

• Zhu W, Pan T, Xie W, Xu P, Jankovic J, Youdim MBH, et al. Comparison of neuroprotective and neurorescue capabilities of rasagiline and selegiline, against lactacystin induced nigrostriatal degeneration. Neurodegener Dis. 2007;4 Suppl 1:90.  [View poster]

Movement Disorder Society (MDS)
10^th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan (Oct. 30 - Nov. 2, 2006)

• Deng H, Le W, Davidson AL, Xie W, Jankovic J. Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor. Mov Disord. 2006;21 Suppl 15:S704. 
• Diamond A, Shahed J, Jankovic J. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. Mov Disord. 2006;21 Suppl 15:S668. 
• Diamond AL, Vuong KD, Jankovic J. Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life. Mov Disord. 2006;21 Suppl 15:S669.  [View poster]
• Hunter CB, Tan EK, Lee J, Shinawi LM, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. Mov Disord. 2006;21 Suppl 15:S411-2.  [View poster]
• Kenney C, Diamond AL, Jankovic J. Hyperhidrosis due to thalamic deep brain stimulation in a patient with essential tremor. Mov Disord. 2006;21 Suppl 15:S667.  [View poster]
• Kenney C, Diamond AL, Mejia N, Hunter CB, Jankovic J. Clinical features that distinguish psychogenic and essential tremor. Mov Disord. 2006;21 Suppl 15:S706.  [View poster]
• Kenney C, Hunter CB, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington disease. Mov Disord. 2006;21 Suppl 15:S635. [Previously Presented]  [View poster]
• Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington disease with 29 trinucleotide repeats. Mov Disord. 2006;21 Suppl 15:S415.  [View poster]
• Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W. Enhancement of autophagy and neuroprotection by rapamycin in lactacystin-induced injury of dopaminergic neurons. Mov Disord. 2006;21 Suppl 15:S505.  [View poster]
• Poysky J, Khan H, Krull K, Jankovic J. Executive dysfunction and comorbid conditions in Tourette syndrome. Mov Disord. 2006;21 Suppl 15:S695-6. 
• Shahed J, Davidson A, Jankovic J. Craving sweets in Parkinson's disease. Mov Disord. 2006;21 Suppl 15:S599.  [View poster]
• Shahed J, Poysky J, Kenney C, Simpson Jr RK, Jankovic J. GPI deep brain stimulation for Tourette syndrome improves tics and psychiatric co-morbidities. Mov Disord. 2006;21 Suppl 15:S693.  [View poster]
• Sitburana O, Jankovic J. Overflow, contralateral and mirror hand dystonia. Mov Disord. 2006;21 Suppl 15:S383-4.  [View poster]
• Wijemanne S, Jankovic J. Hemiparkinsonism-hemiatrophy syndrome. Mov Disord. 2006;21 Suppl 15:S538.  [View poster]
• Wu LJC, Jankovic J. Different faces of hemifacial spasm: Etiological classification. Mov Disord. 2006;21 Suppl 15:S383.  [View poster]
• Wu LJC, Jankovic J. Runner's dystonia. Mov Disord. 2006;21 Suppl 15:S382.  [View poster]
• York MK, Wilde E, Simpson Jr RK, Jankovic J. Relationship of MRI localization and cognition in DBS. Mov Disord. 2006;21 Suppl 15:S609.  [View poster]

American Neurological Association (ANA)
131^st Annual Meeting in Chicago, Ill. (Oct. 8-11, 2006)

• Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, et al. Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor. Ann Neurol. 2006;60 Suppl 10:S74. 
• Deng H, Le W, Hunter CB, Xie W, Mejia N, Jankovic J. A Mexican pedigree with Parkinson's disease, essential tremor and bell's palsy associated with parkin but not HS1BP3 gene mutation. Ann Neurol. 2006;60 Suppl 10:S58. 
• Deng H, Le W, Xie W, Jankovic J. Genetic analysis of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Ann Neurol. 2006;60 Suppl 10:S74. 
• Diamond AL, Vuong KD, Jankovic J. Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life. Ann Neurol. 2006;60 Suppl 10:S77. [Previously Presented]  [View poster]
• Hunter CB, Kenney K, Mejia N, Davidson A, Jankovic J. Medications associated with the onset of tardive dyskinesia. Ann Neurol. 2006;60 Suppl 10:S76.  [View poster]
• Kenney C, Hunter CB, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington disease. Ann Neurol. 2006;60 Suppl 10:S78.  [View poster]

American Academy of Neurology (AAN)
58^th Annual Meeting in San Diego, Calif. (April 1-8, 2006)

• Kenney C, Simpson Jr RK, Hunter CB, Ondo WG, Almaguer M, Davidson A, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. Neurology. 2006;66(5 Suppl 2):A49-50.  [View poster]
• Kenney CJ, Vuong K, Hunter C, Almaguer M, Jankovic J. Long term safety of deep brain stimulation for the treatment of Parkinson's disease. Neurology. 2006;66(5 Suppl 2):A49-50. 
• Pan T, Xie W, Deng H, Zhao H, Jankovic J. Nurrl deficiency predisposes to apoptosis induced by lactacystin in SH-SY5Y cells in vitro. Neurology. 2006;66(5 Suppl 2):A142. 
• Shahed J, Poysky J, Kenney C, Simpson Jr RK, Jankovic J. Bilateral GPI deep brain stimulation for Tourette syndrome. Neurology. 2006;66(5 Suppl 2):A366.  [View poster]
• York MK, Jankovic J, Lai EC, Dulay M . Frontostriatal cognitive functioning 6 months following bilateral subthalamic nucleus deep brain stimulation. Neurology. 2006;66(5 Suppl 2):A213.  [View poster]

International Neuropsychological Society (INS)
34^th Annual Meeting in Boston, Mass. (Feb. 1-4, 2006)

• Dulay MF, York MK, Jankovic J, Simpson Jr RK. Neuropsychological outcome after bilateral deep brain stimulation surgery for advanced Parkinson's disease: Base rates adjusted for practice effects, test unreliability, and natural disease progression. Int J Neurosci. 2006;12(Suppl S1):171.  [View poster]

American Neurological Association (ANA)
130^th Annual Meeting in San Diego, Calif. (Sept. 25-28, 2005)

• Jankovic J, Hunter CB, the BOS Study Group. Botulinum toxin type B Observational Study (BOS). Ann Neurol. 2005;58 Suppl 9:S54. 

American Academy of Neurology (AAN)
57^th Annual Meeting in Miami Beach, Fla. (April 9-16, 2005)

• Deng H, Le W, Zhang X, Pan T, Jankovic J. Genetic analysis of G309D and W4370PA mutations of PINK1 in Parkinson's disease. Neurology. 2005;64(6 Suppl 1):A90. 
• Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins G, et al. New version of the UPDRS: Development methods and working document for field testing. Neurology. 2005;64(6 Suppl 1):A394-5. 
• Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;64(6 Suppl 1):A4. 
• Mejia NI, Jankovic J. Convergence spasm and other psychogenic eye movement disorders. Neurology. 2005;64(6 Suppl 1):A76. 
• Mejia NI, Jankovic J. Tics associated with other disorders. Neurology. 2005;64(6 Suppl 1):A199. 
• Pan T, Xie W, Jankovic J, Le W. HSP70 inducer VPA inhibits rotenone-induced apoptosis in SH-SY5Y cells. Neurology. 2005;64(6 Suppl 1):A199. 
• Shahed J, Diamond AL, Vuong KD, Jankovic J. Characteristics of Parkinson's disease in patients with childhood-onset essential tremor. Neurology. 2005;64(6 Suppl 1):A255. [Previously Presented]  [View poster]
• Silay YS, Jankovic J. Botulinum toxin treatment for oromandibular dystonia and bruxism in patients with Tourette syndrome. Neurology. 2005;64(6 Suppl 1):A200. 

Movement Disorder Society (MDS)
9^th International Congress of Parkinson's Disease and Movement Disorders in New Orleans, La. (March 5-8, 2005)

• Azher SN, Vuong KD, Shahed J, Diamond AL, Jankovic J . Gait and balance assessment in parkinsonian disorders. Mov Disord. 2005;20 Suppl 10:S112-3.  [View poster]
• Deng H, Jankovic J, Pan T, Xie W, Le W. Small interfering RNA (SiRNA) targeting the PINK1 induces apoptosis in human SH-SY5Y cells. Mov Disord. 2005;20 Suppl 10:S127. 
• Deng H, Jankovic J, Xie W, Pan T, Le W. Reduced NURR1 gene expression affects expression of dopaminergic phenotypic markers and Parkinson's disease-related genes. Mov Disord. 2005;20 Suppl 10:S143. 
• Diamond AL, Shahed J, Azher SN, Vuong KD, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2005;20 Suppl 10:S153-4.  [View poster]
• Dulay MF, Levin HS, Jankovic J, Lai EC, York MK . Relationship among psychiatric, motor and cognitive functioning in non-demented individuals with Parkinson's disease. Mov Disord. 2005;20 Suppl 10:S144.  [View poster]
• Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine: Does prior history of depression preclude this drug as a treatment option? Mov Disord. 2005;20 Suppl 10:S47.  [View poster]
• Jankovic J, Hunter C, Atassi MZ, Dolimbek BZ, Dolimbek GS, and BOS Research Group. Botulinum toxin type B Observational Study (BOS). Mov Disord. 2005;20 Suppl 10:S31.  [View poster]
• Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States. Mov Disord. 2005;20 Suppl 10:S22. 
• Mejia N, Vuong KD, Hunter C, Jankovic J. Medications associated with the onset of tardive dyskinesia. Mov Disord. 2005;20 Suppl 10:S18.  [View poster]
• Ondo WG, Meilak C, Vuong KD, Jankovic J. Predictors of battery life for the Activa® Soletra 7426 neurostimulator. Mov Disord. 2005;20 Suppl 10:S160-1.  [View poster]
• Ondo WG, Silay Y, Almaguer M, Jankovic J. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2005;20 Suppl 10:S163.  [View poster]
• Shahed J, Diamond AL, Vuong KD, Jankovic J. Characteristics of Parkinson's disease in patients with childhood-onset essential tremor. Mov Disord. 2005;20 Suppl 10:S169-70.  [View poster]
• Tintner R, Silay YS, Sessoms S, Jankovic J. Parkinsonism associated with adalimumab in a patient with rheumatoid arthritis. Mov Disord. 2005;20 Suppl 10:S16. 

American Neurological Association (ANA)
129^th Annual Meeting in Toronto, Canada (Oct. 4-5, 2004)

• Comella CL, Jankovic J, Leurgans S, Fan W, Chmura T, the Dystonia Study Group. Botulinum toxin serotype A compared to B in cervical dystonia: Randomized, double-blind, parallel study. Ann Neurol. 2004;56 Suppl 8:S25. 
• Silay Y, Jankovic J, Vuong KD, Almageur M, Ondo WG, Tintner R, et al. The safety of deep brain stimulation in patients with Parkinson's disease, essential tremor, and other movement disorders. Ann Neurol. 2004;56 Suppl 8:S54-5.  [View poster]

Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders
18^th Annual Symposium in Toronto, Canada (Oct. 3, 2004)

• Jankovic J, Hunter CB, Vuong KD . Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas. Mov Disord. 2004;19(9):1127.  [View poster]
• Tintner R for the Tremor Research Group. The Tremor Rating Scale (TRS). Mov Disord. 2004;19(9):1131-2.  [View poster]

Movement Disorder Society (MDS)
8^th International Congress of Parkinson's Disease and Movement Disorders in Rome, Italy (June 13-17, 2004)

• Hunter C, Vuong KD, Mejia N, Jankovic J . Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome. Mov Disord. 2004;19 Suppl 9:S437.  [View poster]
• Jankovic J, Hunter C, Mejia N, Vuong KD. Tetrabenazine: Effective treatment for tardive dyskinesia. Mov Disord. 2004;19 Suppl 9:S73.  [View poster]
• Jankovic J, Ondo WG, Stacy MA, Elble RJ, Pahwa R, Connor GS, et al. A multicenter, double-blind, placebo-controlled trial of topiramate in essential tremor. Mov Disord. 2004;19 Suppl 9:S448-9. 
• Le W, Jiang Q, Xie W, Hintermann S, Jankovic J. Nurr1 gene targeting therapy for Parkinson disease. Mov Disord. 2004;19 Suppl 9:S132. 
• Pan T, Xie W, Jankovic J, Le W. The pharmacological and biological effects of pramipexole on dopamine neuron associated genes: DAT, VMAT-2, and Nurr1. Mov Disord. 2004;19 Suppl 9:S215. 
• Silver GA, Vuong KD, Jankovic J. Young-onset versus late-onset Parkinson's disease: Clinical features and disease progression. Mov Disord. 2004;19 Suppl 9:S264.  [View poster]
• Thomas M, Banuelos P, Vuong KD, Jankovic J. Long-term prognosis of psychogenic movement disorders. Mov Disord. 2004;19 Suppl 9:S431.  [View poster]
• Thomas M, Vuong KD, Jankovic J. Psychogenic dystonia: Clinical characteristics and long-term progression. Mov Disord. 2004;19 Suppl 9:S111.  [View poster]
• Tintner R, Gross RL, Winzer UF, Smalky KA, Jankovic J. A double-blind, randomized, parallel group design comparison of botulinum toxin, type A (Botox) and botulinum toxin, type B (Myobloc) on systemic and ocular autonomic symptoms and physiology in patients with cervical dystonia. Mov Disord. 2004;19 Suppl 9:S398. 
• Vuong KD, Hunter C, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov Disord. 2004;19 Suppl 9:S422.  [View poster]
• York MK, Silay YS, Chaytor N, Simpson Jr RK, Jankovic J. Is depression a predictor of outcome after bilateral subthalamic deep brain stimulation in patients with Parkinson's disease? Mov Disord. 2004;19 Suppl 9:S174.  [View poster]

American Academy of Neurology (AAN)
56^th Annual Meeting in San Francisco, Calif. (April 24 - May 1, 2004)

• Azher S, Jankovic J. Camptocormia: Pathogenesis, classification and response to therapy. Neurology. 2004;62(7 Suppl S5):A51.  [View poster]
• Comella CL, Jankovic J, Daggett S, Mordaunt J, Brin MF. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia. Neurology. 2004;62(7 Suppl S5):A511. 
• Higgins JJ, Lombardi RQ, Tan EK, Jankovic J, Pucilowska J, Rooney JP. Haplotype analysis at the ETM2 locus in American and Singaporean populations with familial essential tremor. Neurology. 2004;62(7 Suppl S5):A27. 
• Hunter CB, Vuong KD, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Neurology. 2004;62(7 Suppl S5):A506-7.  [View poster]
• Jankovic J, Madisetty J, Vuong KD. Essential tremor in children. Neurology. 2004;62(7 Suppl S5):A502.  [View poster]
• Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: Long-term outcome. Neurology. 2004;62(7 Suppl S5):A501.  [View poster]
• Jiang C, Pan T, Jankovic J, Le W. Effects of ropinirole on progression of parkinsonism in Nurr1-deficient mice and its underlying mechanisms. Neurology. 2004;62(7 Suppl S5):A7. 
• Jiang C, Wan X, Jankovic J, Christian S, Sundsmo J, Le W. Dopaminergic properties and anti-parkinsonian effects of IPX750 in rodent models of Parkinson's disease. Neurology. 2004;62(7 Suppl S5):A9. 
• Pan T, Jankovic J, Le W. The pharmacological and biological effects of pramipexole on dopamine transporter. Neurology. 2004;62(7 Suppl S5):A109. 
• Pan T, Xie W, Jankovic J, Le W. Decreased Nurr1 mRNA in peripheral blood lymphocytes in Parkinson's disease. Neurology. 2004;62(7 Suppl S5):A108. 
• Silay YS, Vuong KD, Jankovic J . The efficacy and safety of fluphenazine in patients with Tourette syndrome. Neurology. 2004;62(7 Suppl S5):A506.  [View poster]
• Tintner R, Winzer UF, Smalky KA, Jankovic J. A double-blind, randomized, parallel group design comparison of botulinum toxin, type A (Botox®) and botulinum toxin, type B (Myobloc™) on autonomic symptoms and physiology in patients with cervical dystonia. Neurology. 2004;62(7 Suppl S5):A538. 

American Society for Experimental NeuroTherapeutics (ASENT)
6^th Annual Meeting in Bethesda, Md. (March 11-13, 2004)

• Jankovic J, Hunter CB, Vuong KD . Tetrabenazine in the treatment of chorea. Presented at the American Society for Experimental NeuroTherapeutics (ASENT), 6^th Annual Meeting in Bethesda, Md. (March 11-13, 2004).   [View poster]

International Neuropsychological Society (INS)
32^nd Annual Meeting in Baltimore, Md. (Feb. 4-7, 2004)

• York MK, Levin HS, Soety EM, Lai EC, Jankovic J, Grossman RG. Information processing speed influences the component processes of verbal working memory in Parkinson's disease patients. Int J Neurosci. 2004;10 Supple S1:67.  [View poster]

American Academy of Neurology (AAN)
55^th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)

• Higgins JJ, Jankovic J, Lombardi RQ, Pucilowska J, Tan EK, Ashizawa T, et al. Haplotype analysis of unrelated individuals with familial essential tremor. Neurology. 2003;60(5 Suppl 1):A269-70. 
• Kuniyoshi S, Tintner R, Ondo W, Simpson R, Jankovic J. Comparison of postoperative improvement of staged bilateral subthalamic stimulation in patients with advanced Parkinson's disease. Neurology. 2003;60(5 Suppl 1):A120. 
• Li Y-J, Martin ER, Scott WK, Haines JL, Nance MA, Hubble JP, et al. Apolipoprotein E controls risk and age at onset of Parkinson disease. Neurology. 2003;60(5 Suppl 1):A127-8. 
• Li Y-J, Oliveria AS, Hauser MA, Hauser ER, Scott WK, Stenger JE, et al. Glutathione S-Transferase, Omega-1 (GSTO1) modifies age at onset of Alzheimer disease and Parkinson disease. Neurology. 2003;60(5 Suppl 1):A68-9. 
• Tintner R, Kuniyoshi SM, Gonzalez A, Jankovic J. The epidemiology of myoclonus in the medical and surgical intensive care unit (ICU). Neurology. 2003;60(5 Suppl 1):A440. 
• Van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Haines JL, McLaurin AC, et al. Specific mitochondrial haplogroups affect risk for late-onset Parkinson disease. Neurology. 2003;60(5 Suppl 1):A438. 

Movement Disorder Society (MDS)
7^th International Congress of Parkinson's Disease and Movement Disorders in Miami, Fla. (Nov. 10-14, 2002)

• Hill AN, Jankovic J, Vuong KD, Donovan D . Treatment of hypophonia with collagen vocal fold augmentation in patients with parkinsonism. Mov Disord. 2002;17 Suppl 5:S105.  [View poster]
• Hunter CB, Wang A, Vuong KD, Jankovic J . Age-related tolerability of tetrabenazine. Mov Disord. 2002;17 Suppl 5:S41.  [View poster]
• Hunter CB, Wang A, Vuong KD, Jankovic J . Tetrabenazine in the treatment of Tourette syndrome. Mov Disord. 2002;17 Suppl 5:S341.  [View poster]
• Kwak CH, Jankovic J. Premonitory sensations in tics. Mov Disord. 2002;17 Suppl 5:S339-40. 
• Le W, Imam SZ, Xie W, Ali S, Jankovic J. Reduced Nurr1 expression increases the susceptibility to dopaminergic toxins via nitric oxide. Mov Disord. 2002;17 Suppl 5:S27. 
• Ondo WG, Cohen H, Almaguer M, Jankovic J . Computerized posturography balance assessment of patients with bilateral vim deep brain stimulation. Mov Disord. 2002;17 Suppl 5:S190-1.  [View poster]
• Pan TH, Xu PY, Xie WJ, Hunter C, Jankovic J, Le WD. Upregulation of Nurr1 gene expression by dopamine receptor agonist pramipexole in human neuroblastoma SHSY-5Y cells. Mov Disord. 2002;17 Suppl 5:S84. 
• Protas EJ, Thomas M, Cunha IT, Caroline KS, Wankadia S, Jankovic J. Reliability of limits of stability measures in Parkinson's disease. Mov Disord. 2002;17 Suppl 5:S128-9. 
• Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: A pilot study. Mov Disord. 2002;17 Suppl 5:S237. 
• Thomas M, Jankovic J, Suteerawattanon M, Wankadia S, Caroline K, Protas E. Gait and Balance Scale (GABS): Validation and utilization. Mov Disord. 2002;17 Suppl 5:S235. 
• Tintner R, Almaguer M, Sanghera M, Simpson R, Ondo WG, Jankovic J. Experience with bilateral subthalamic nucleus (STN) stimulation for Parkinson's disease (PD). Mov Disord. 2002;17 Suppl 5:S196. 
• Tintner R, Almaguer M, Vuong KD, Ondo WG, Jankovic J, Sanghera M. Predictors of response to bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord. 2002;17 Suppl 5:S208. 
• Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after 11 years of pergolide treatment. Mov Disord. 2002;17 Suppl 5:S48. 
• Truong DD, Duane DD, Jankovic J, Singer C, Comella CL, the US Dysport Dystonia Study Group. The efficacy and safety of Dysport (botulinum type A toxin) in cervical dystonia: Results of the first US study. Mov Disord. 2002;17 Suppl 5:S306. 

American Neurological Association (ANA)
127^th Annual Meeting in New York City, N.Y. (Oct. 12-16, 2002)

• Hou JG, Jankovic J. Dystonia in Friedreich's ataxia. Ann Neurol. 2002;52 Suppl 3:S82-3. 

Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins
International Conference in Hannover, Germany (June 8, 2002)

• Jankovic J, Ahsan J, Vuong KD. Comparison of immunogenicity of old versus current Botox in cervical dystonia. Presented at the Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, International Conference in Hannover, Germany (June 8, 2002).   [View poster]

American Academy of Neurology (AAN)
53^rd Annual Meeting in Philadelphia, Penn. (May 5-11, 2001)

• Atassi F, Vuong KD, Jankovic J, Ondo WG. The prevalence of restless legs syndrome in patients with Parkinson's disease. Neurology. 2001;56(8 Suppl 3):A21. 
• Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson's disease and restless legs syndrome. Neurology. 2001;56(8 Suppl 3). 

Movement Disorder Society (MDS)
6^th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000)

• Ondo WG, Hunter C, Vuong KD, Jankovic J. Olanzapine treatment for dopaminergic induced hallucinations. Presented at the Movement Disorder Society (MDS), 6^th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).  
• Ondo WG, Vuong KD, Atassi F, Khan H, Kwak C, Jankovic J. Daytime sleepiness in patients with Parkinson's disease. Presented at the Movement Disorder Society (MDS), 6^th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).  

American Academy of Neurology (AAN)
52^nd Annual Meeting in San Diego, Calif. (April 29 - May 6, 2000)

• Vuong KD, Ondo WG, Almaguer M, Simpson RK, Jankovic J. Unilateral thalamic deep brain stimulation for essential tremor and Parkinson's disease: Effects of stimulation on the non-target limb and rebound augmentation. Neurology. 2000;54(Suppl 3):A54. 

American Academy of Neurology (AAN)
46^th Annual Meeting in Washington, DC (May 1-7, 1994)

• Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs. Neurology. 1994;44(4 Suppl 2):A194. 

International Neuropsychological Society (INS)
22^nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)

• Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease. Int J Neurosci. 1994;43. 

American Neurological Association (ANA)
118^th Annual Meeting in Boston, Mass. (Oct. 18-20, 1993)

• Shoulson I, Parkinson Study Group. The impact of extended deprenyl treatment in Parkinson's disease patients not requiring levodopa therapy. Ann Neurol. 1993;34(2):263. 

American Academy of Neurology (AAN)
43^rd Annual Meeting in Boston, Mass. (April 21-27, 1991)

• Doody RS, Jankovic J. The alien hand and related signs. Neurology. 1991;41(3 Suppl 1).